A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Johanna C. Bendell, Milind Javle, Tanios S. Bekaii-Saab, Richard S. Finn, Zev A. Wainberg, Daniel A. Laheru, Colin D. Weekes, Benjamin R. Tan, Gazala N. Khan, Mark M. Zalupski, Jeffrey R. Infante, Suzanne Jones, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Renae E. Chavira, Janna L. Christy-Bittel, Emma Barrett, Amita Patnaik

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences